Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

November 13, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

July 10, 2022

Conditions
Influenza and Pneumonia
Interventions
BIOLOGICAL

Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.

BIOLOGICAL

Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.

Trial Locations (4)

214527

Jingjiang Center for Diseases Control and Prevention, Taizhou

225309

Taizhou City Hospital of Traditional Chinese and Western Medicine, Taizhou

225323

Gaogang District Center for Disease Control and Prevention, Taizhou

225799

Xinghua Center for Disease Control and Prevention, Taizhou

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT05471531 - Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine | Biotech Hunter | Biotech Hunter